Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Aramark's Q3 Revenue Jumps 9% to $5.06 Billion

Aramark’s third-quarter revenue rose 9% from a year earlier to $5.06 billion, with organic revenue also up 9%. The company said revenue growth would have been about 11% without the calendar shift tied to the 53rd week in fiscal 2025.

Operating income increased 18% to $216 million, while adjusted operating income climbed 13% to $261 million. Without the calendar shift, Aramark said operating income growth would have been about 29% and adjusted operating income growth about 21%.

Earnings per share increased sharply as well. GAAP EPS rose 34% to $0.36, while adjusted EPS increased 29% to $0.52. On a constant-currency basis, those gains would have been about 55% and 43%, respectively, the company said.

By segment, FSS United States revenue increased 8% to $3.50 billion, and FSS International revenue rose 13% to $1.56 billion. Operating income in FSS United States increased 14% to $182 million, while FSS International operating income increased 40% to $69 million. Adjusted operating income rose 12% in FSS United States to $211 million and 26% in FSS International to $85 million.

Cash generation improved in the quarter. Net cash provided by operating activities increased by $41 million, and free cash flow rose by $42 million. Aramark ended the quarter with more than $1.4 billion of cash availability and later repaid about $100 million of 2028 term loans.

The company also lifted its full-year organic revenue growth outlook to 9% to 10%, up from a prior range at the high end of 7% to 9%. It kept its full-year adjusted operating income growth outlook at 12% to 17%, adjusted EPS growth at 20% to 25%, and leverage ratio target below 3x. Following these announcements, the company's shares moved 8.22%, and are now trading at a price of $60.29. If you want to know more, read the company's complete 8-K report here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS